Patient Survival and Tumor Characteristics Associated with CHEK2:p.I157T - Findings from the Breast Cancer Association Consortium

Background: P.I157T is a CHEK2 missense mutation associated with a modest increase in breast cancer risk. Previously, another CHEK2 mutation, the protein truncating c.1100delC has been associated with poor prognosis of breast cancer patients. Here, we have investigated patient survival and characteristics of breast tumors of germ line p.I157T carriers.

Methods: We included in the analyses 26,801 European female breast cancer patients from 15 studies participating in the Breast Cancer Association Consortium. We analyzed the association between p.I157T and the clinico-pathological breast cancer characteristics by comparing the p.I157T carrier tumors to non-carrier and c.1100delC carrier tumors. Similarly, we investigated the p.I157T associated risk of early death, breast cancer-associated death, distant metastasis, locoregional relapse and second breast cancer using Cox proportional hazards models. Additionally, we explored the p.I157T-associated genomic gene expression profile using data from breast tumors of 183 Finnish female breast cancer patients (ten p.I157T carriers) (GEO: GSE24450). Differential gene expression analysis was performed using a moderated t test. Functional enrichment was investigated using the DAVID functional annotation tool and gene set enrichment analysis (GSEA). The tumors were classified into molecular subtypes according to the St Gallen 2013 criteria and the PAM50 gene expression signature.

Results: P.I157T was not associated with increased risk of early death, breast cancer-associated death or distant metastasis relapse, and there was a significant difference in prognosis associated with the two CHEK2 mutations, p.I157T and c.1100delC. Furthermore, p.I157T was associated with lobular histological type and clinico-pathological markers of good prognosis, such as ER and PR expression, low TP53 expression and low grade. Gene expression analysis suggested luminal A to be the most common subtype for p.I157T carriers and CDH1 (cadherin 1) target genes to be significantly enriched among genes, whose expression differed between p.I157T and non-carrier tumors.

Conclusions: Our analyses suggest that there are fundamental differences in breast tumors of CHEK2:p.I157T and c.1100delC carriers. The poor prognosis associated with c.1100delC cannot be generalized to other CHEK2 mutations.

Citing Articles

Germline predisposition in multiple myeloma.

Rodrigues F, Jasielec J, Perpich M, Kim A, Moma L, Li Y iScience. 2025; 28(1):111620.

PMID: 39845416 PMC: 11750583. DOI: 10.1016/j.isci.2024.111620.

Gender-Specific Genetic Predisposition to Breast Cancer: Genes and Beyond.

Valentini V, Bucalo A, Conti G, Celli L, Porzio V, Capalbo C Cancers (Basel). 2024; 16(3).

PMID: 38339330 PMC: 10854694. DOI: 10.3390/cancers16030579.

Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer.

Turchiano A, Piglionica M, Martino S, Bagnulo R, Garganese A, De Luisi A Genes (Basel). 2023; 14(8).

PMID: 37628581 PMC: 10454640. DOI: 10.3390/genes14081530.

Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Hanson H, Astiazaran-Symonds E, Amendola L, Balmana J, Foulkes W, James P Genet Med. 2023; 25(10):100870.

PMID: 37490054 PMC: 10623578. DOI: 10.1016/j.gim.2023.100870.

Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.

Oropeza E, Seker S, Carrel S, Mazumder A, Lozano D, Jimenez A Sci Adv. 2023; 9(26):eadf2860.

PMID: 37390209 PMC: 10313178. DOI: 10.1126/sciadv.adf2860.

References

Cheang M, Martin M, Nielsen T, Prat A, Voduc D, Rodriguez-Lescure A . Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015; 20(5):474-82. PMC: 4425383. DOI: 10.1634/theoncologist.2014-0372. View

Boquest A, Shahdadfar A, Fronsdal K, Sigurjonsson O, Tunheim S, Collas P . Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell. 2005; 16(3):1131-41. PMC: 551479. DOI: 10.1091/mbc.e04-10-0949. View

Pond A, Bin X, Batts T, Roarty K, Hilsenbeck S, Rosen J . Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells. 2012; 31(1):178-89. PMC: 3690809. DOI: 10.1002/stem.1266. View

Dunnwald L, Rossing M, Li C . Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9(1):R6. PMC: 1851385. DOI: 10.1186/bcr1639. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Prat A, Chon U Cheang M, Martin M, Parker J, Carrasco E, Caballero R . Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2012; 31(2):203-9. PMC: 3532392. DOI: 10.1200/JCO.2012.43.4134. View

Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N . Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2005; 25(15):2273-84. DOI: 10.1038/sj.onc.1209254. View

Jechlinger M, Grunert S, Tamir I, Janda E, Ludemann S, Waerner T . Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003; 22(46):7155-69. DOI: 10.1038/sj.onc.1206887. View

Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson J . Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS. 1997; 105(2):121-30. DOI: 10.1111/j.1699-0463.1997.tb00550.x. View

10.

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

11.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M, Shih I . Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53. DOI: 10.1038/modpathol.2011.85. View

12.

Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W . Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat. 2011; 132(3):937-45. DOI: 10.1007/s10549-011-1635-7. View

13.

Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J . Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer. 2004; 113(4):575-80. DOI: 10.1002/ijc.20638. View

14.

Bell D, Kim S, Godwin A, Schiripo T, Harris P, Haserlat S . Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007; 121(12):2661-7. PMC: 3090684. DOI: 10.1002/ijc.23026. View

15.

Huzarski T, Cybulski C, Wokolorczyk D, Jakubowska A, Byrski T, Gronwald J . Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Res Treat. 2014; 144(2):397-403. DOI: 10.1007/s10549-014-2865-2. View

16.

Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, Babikyan D . Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res. 2011; 13(1):R6. PMC: 3109572. DOI: 10.1186/bcr2810. View

17.

de Bock G, Schutte M, Krol-Warmerdam E, Seynaeve C, Blom J, Brekelmans C . Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004; 41(10):731-5. PMC: 1735606. DOI: 10.1136/jmg.2004.019737. View

18.

Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J . Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011; 29(28):3747-52. DOI: 10.1200/JCO.2010.34.0778. View

19.

Anczukow O, Ware M, Buisson M, Zetoune A, Stoppa-Lyonnet D, Sinilnikova O . Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?. Hum Mutat. 2007; 29(1):65-73. DOI: 10.1002/humu.20590. View

20.

Huzarski T, Cybulski C, Domagala W, Gronwald J, Byrski T, Szwiec M . Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res Treat. 2005; 90(2):187-9. DOI: 10.1007/s10549-004-3778-2. View